Patient characteristics and demographics.
| Characteristic | All RA, n = 28 | EULAR Responders, n= 17 | EULAR Nonresponders, n = 11 | P |
|---|---|---|---|---|
| Sex (male/female) | 26/2 | 16/1 | 10/1 | |
| Age, yrs (mean ± SD) | 49 ± 13 | 484 ± 14.8 | 48.5 ± 11.7 | NS |
| Disease duration (mean ± SD), yrs | 7.3 ± 6.0 | 8.3 ± 7.5 | 6.0 ± 5.1 | NS |
| Rheumatoid factor-positive (n, %) | 20 (71.4) | 12 (70.5) | 8 (72.2) | NS |
| Erosion on radiographs, n (%) | 14 (50) | 7 (41.1) | 7 (63.3) | <0.05 |
| DAS28 ESR | 5.1 (4.5–5.6) | 54 (4.8–5.8) | 5.0 (3.7–5.6) | NS |
| CRP, mg/l | 12.2 (5.6–28.3) | 13.1 (5.7–40.7) | 11.3 (5.5–23.4) | NS |
| ESR, mm/h | 38.0 (25.2–78.7) | 40 (25.5–82) | 36 (20.0–75.0) | NS |
| Physician global assessment | 6.2 (5.0–8.0) | 7.0 (5.0–8.0) | 6.0 (5.0–8.0) | NS |
| Swollen joint count | 7.0 (5.0–9.2) | 6 (5.0–9.0) | 8 (5.0–10.0) | NS |
| Tender joint count | 8.0 (4.7–13.2) | 11 (6.0–15) | 5.0 (4.0–9.0) | NS |
| HAQ score | 1.1 (1.0–1.6) | 1.12 (1.0–1.68) | 1.0 (0.87–1.62) | NS |
| Patient global assessment | 6.0 (6.7–7.0) | 7.0 (6.0–8.0) | 6.0 (6.0–7.0) | NS |
Data are expressed as median (interquartile range). EULAR: European League Against Rheumatism; DAS: Disease Activity Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; NS: not significant.